A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer
To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian...
Saved in:
| Published in: | Radiation oncology (London, England) Vol. 7; no. 1; p. 111 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
23-07-2012
BioMed Central BMC |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer.
Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated.
Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250-293) for 3D-CRT; 824 (range 641-1083) for IMRT; and 403 (range 333-489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01-3:09) for 3D-CRT; 4:39 (range 3:41-6:40) for IMRT; and 1:14 (range 1:13-1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum.
VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. |
|---|---|
| AbstractList | To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated. Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250-293) for 3D-CRT; 824 (range 641-1083) for IMRT; and 403 (range 333-489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01-3:09) for 3D-CRT; 4:39 (range 3:41-6:40) for IMRT; and 1:14 (range 1:13-1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum. VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. BACKGROUND: To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. METHODS: Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated. RESULTS: Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250-293) for 3D-CRT; 824 (range 641-1083) for IMRT; and 403 (range 333-489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01-3:09) for 3D-CRT; 4:39 (range 3:41-6:40) for IMRT; and 1:14 (range 1:13-1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum. CONCLUSIONS: VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated. Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250-293) for 3D-CRT; 824 (range 641-1083) for IMRT; and 403 (range 333-489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01-3:09) for 3D-CRT; 4:39 (range 3:41-6:40) for IMRT; and 1:14 (range 1:13-1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum. VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. Doc number: 111 Abstract Background: To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. Methods: Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated. Results: Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250-293) for 3D-CRT; 824 (range 641-1083) for IMRT; and 403 (range 333-489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01-3:09) for 3D-CRT; 4:39 (range 3:41-6:40) for IMRT; and 1:14 (range 1:13-1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum. Conclusions: VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. Abstract Background To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. Methods Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated. Results Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250–293) for 3D-CRT; 824 (range 641–1083) for IMRT; and 403 (range 333–489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01–3:09) for 3D-CRT; 4:39 (range 3:41–6:40) for IMRT; and 1:14 (range 1:13–1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum. Conclusions VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. Background To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder cancer. Methods Radiotherapy plans for 15 patients with T2-T4N0M0 bladder cancer were prospectively developed for 3-DCRT, IMRT and VMAT using Varian Eclipse planning system. The same radiation therapist carried out all planning and the same clinical dosimetric constraints were used. 10 of the patients with well localised tumours had a simultaneous infield boost (SIB) of the primary tumour planned for both IMRT and VMAT. Tumour control probabilities and normal tissue complication probabilities were calculated. Results Mean planning time for 3D-CRT, IMRT and VMAT was 30.0, 49.3, and 141.0 minutes respectively. The mean PTV conformity (CI) index for 3D-CRT was 1.32, for IMRT 1.05, and for VMAT 1.05. The PTV Homogeneity (HI) index was 0.080 for 3D-CRT, 0.073 for IMRT and 0.086 for VMAT. Tumour control and normal tissue complication probabilities were similar for 3D-CRT, IMRT and VMAT. The mean monitor units were 267 (range 250-293) for 3D-CRT; 824 (range 641-1083) for IMRT; and 403 (range 333-489) for VMAT (P < 0.05). Average treatment delivery time were 2:25min (range 2:01-3:09) for 3D-CRT; 4:39 (range 3:41-6:40) for IMRT; and 1:14 (range 1:13-1:14) for VMAT. In selected patients, the SIB did not result in a higher dose to small bowel or rectum. Conclusions VMAT is associated with similar dosimetric advantages as IMRT over 3D-CRT for muscle invasive bladder cancer. VMAT is associated with faster delivery times and less number of mean monitor units than IMRT. SIB is feasible in selected patients with localized tumours. Keywords: Bladder cancer, Intensity modulated radiation therapy, Volumetric modulated arc therapy |
| ArticleNumber | 111 |
| Audience | Academic |
| Author | Bressel, Mathias Cramb, Jim Pham, Daniel Foroudi, Farshad Wilson, Lesley Gill, Suki Tai, Keen Hun Kron, Tomas Haworth, Annette Hornby, Colin |
| AuthorAffiliation | 3 Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 1 Division of Radiation Oncology, Peter MacCallum Cancer Center, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC, 3002, Australia 2 Radiation Therapy Services, Peter MacCallum Cancer Center, Melbourne, VIC, Australia 4 Physical Sciences, Peter MacCallum Cancer Center, Melbourne, VIC, Australia |
| AuthorAffiliation_xml | – name: 1 Division of Radiation Oncology, Peter MacCallum Cancer Center, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC, 3002, Australia – name: 2 Radiation Therapy Services, Peter MacCallum Cancer Center, Melbourne, VIC, Australia – name: 3 Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia – name: 4 Physical Sciences, Peter MacCallum Cancer Center, Melbourne, VIC, Australia |
| Author_xml | – sequence: 1 givenname: Farshad surname: Foroudi fullname: Foroudi, Farshad email: farshad.foroudi@petermac.org organization: Division of Radiation Oncology, Peter MacCallum Cancer Center, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC, 3002, Australia. farshad.foroudi@petermac.org – sequence: 2 givenname: Lesley surname: Wilson fullname: Wilson, Lesley – sequence: 3 givenname: Mathias surname: Bressel fullname: Bressel, Mathias – sequence: 4 givenname: Annette surname: Haworth fullname: Haworth, Annette – sequence: 5 givenname: Colin surname: Hornby fullname: Hornby, Colin – sequence: 6 givenname: Daniel surname: Pham fullname: Pham, Daniel – sequence: 7 givenname: Jim surname: Cramb fullname: Cramb, Jim – sequence: 8 givenname: Suki surname: Gill fullname: Gill, Suki – sequence: 9 givenname: Keen Hun surname: Tai fullname: Tai, Keen Hun – sequence: 10 givenname: Tomas surname: Kron fullname: Kron, Tomas |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22824133$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk1r3DAQhk1JaT7ac29F0LMTy5Jl-VLYpl-BQC8t9CZG0mijxba2kr10f0D_d7XdTZqFFB0kXs08zMw758XJGEYsite0uqRUiivaclm2tP1VtiWl9Flxdq_8OHn0Pi3OU1pVFW9Y1b0oTuta1pwydlb8XhAbkh9wit4QE4Y1RJ_CSIIj7EMWRhfiAD3ZJOLHCcfkpy0Zgp17mNDu5E3o50M-REMiWA-Tz4jpDiOstyQTyDAn02NGbCD5DRLdg7UYiYHRYHxZPHfQJ3x1uC-K758-frv-Ut5-_XxzvbgttWi7qdS1kLKRjKFAzluAxjjhwDSIVDirbe5Q1Fya1tEOAUxnoQaK0HTaCd2xi-Jmz7UBVmod_QBxqwJ49VcIcakgTj5XqipgrZXa2JpCHpWWFhohHKcopdY1ZNa7PWs96wGtwXGK0B9Bj39Gf6eWYaMY55wJlgHv9wDtw38Axz_ZHbWzVO0sVa3KhmfI20MVMfycMU1qFeY45iEqWsmqbfJAun9RS8it-expBprBJ6MWDeOMdrzesS6fiMrH4uDzJqDzWT9KuNonmBhSiugeiqeV2u3nE-W-eTy0h_j7hWR_ACJb5kU |
| CitedBy_id | crossref_primary_10_1016_j_jrras_2014_10_008 crossref_primary_10_1007_s00066_015_0859_6 crossref_primary_10_4103_jmp_jmp_156_23 crossref_primary_10_1186_s13014_016_0618_6 crossref_primary_10_1016_j_canrad_2013_06_024 crossref_primary_10_1016_j_meddos_2015_06_002 crossref_primary_10_1016_j_clineuro_2019_105573 crossref_primary_10_1186_s13014_015_0499_0 crossref_primary_10_1016_j_clon_2022_05_003 crossref_primary_10_4103_jrcr_jrcr_19_22 crossref_primary_10_1186_1748_717X_9_109 crossref_primary_10_1016_j_ijrobp_2015_12_379 crossref_primary_10_1007_s00411_013_0497_2 crossref_primary_10_3389_fonc_2021_637591 crossref_primary_10_1016_j_ijrobp_2012_11_035 crossref_primary_10_1177_0300891618766114 crossref_primary_10_1017_S1460396921000431 crossref_primary_10_1177_0300891618766111 crossref_primary_10_4103_jmp_jmp_11_24 crossref_primary_10_1002_acm2_13587 crossref_primary_10_1016_j_canrad_2014_08_006 crossref_primary_10_1186_s13014_023_02348_8 crossref_primary_10_1016_j_clon_2014_03_007 crossref_primary_10_1016_j_ijrobp_2017_01_239 crossref_primary_10_1016_j_clon_2021_02_002 crossref_primary_10_1016_j_meddos_2016_09_003 crossref_primary_10_1259_bjr_20200125 crossref_primary_10_36290_xon_2019_039 crossref_primary_10_3390_gels8090582 crossref_primary_10_3233_BLC_170137 crossref_primary_10_1016_j_clon_2019_09_056 |
| Cites_doi | 10.1016/j.radonc.2007.04.037 10.1016/j.radonc.2006.06.015 10.1016/j.ijrobp.2005.09.044 10.1016/j.ijrobp.2008.11.040 10.1016/j.ijrobp.2010.10.024 10.1186/1748-717X-5-95 10.1016/j.radonc.2009.08.015 10.3171/jns.2000.93.supplement_3.0219 10.1007/BF03178629 10.1118/1.2818738 10.1016/S0360-3016(03)01031-9 10.1016/j.clon.2011.06.006 10.1016/j.ijrobp.2007.08.046 10.1016/j.ijrobp.2009.05.071 10.1200/JCO.2008.19.5776 10.1016/j.radonc.2009.08.011 10.1016/j.ijrobp.2010.04.025 10.1016/j.clon.2009.01.016 10.1016/j.ijrobp.2009.03.078 10.1111/j.1754-9485.2011.02336.x 10.1186/1748-717X-6-75 10.1016/j.radonc.2010.01.011 10.1016/j.ijrobp.2009.04.037 10.1016/S0167-8140(00)00281-4 10.1016/j.ijrobp.2008.02.047 10.1016/j.ejmp.2007.07.001 10.1016/j.ijrobp.2006.07.013 10.3109/0284186X.2010.498431 10.1186/1748-717X-5-110 10.1016/j.ijrobp.2010.06.061 10.1016/j.radonc.2008.06.013 10.1016/j.ijrobp.2006.01.027 10.1016/S0360-3016(03)00073-7 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 BioMed Central Ltd. 2012 Foroudi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Foroudi et al.; licensee BioMed Central Ltd. 2012 Foroudi et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: 2012 Foroudi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Foroudi et al.; licensee BioMed Central Ltd. 2012 Foroudi et al.; licensee BioMed Central Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QO 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH K9. M0S M1P P64 PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA |
| DOI | 10.1186/1748-717x-7-111 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Biotechnology Research Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Technology Research Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library Biotechnology Research Abstracts ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Engineering Research Database ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1748-717X |
| EndPage | 111 |
| ExternalDocumentID | oai_doaj_org_article_0a37d8bcd21a413b8da566f41e88bb2a oai_biomedcentral_com_1748_717X_7_111 2772077231 A534319421 10_1186_1748_717X_7_111 22824133 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GeographicLocations | Australia United States |
| GeographicLocations_xml | – name: Australia – name: United States |
| GroupedDBID | --- -A0 0R~ 123 29P 2VQ 2WC 3V. 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EBD EBLON EBS ECM EIF EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE I-F IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SMD SOJ TUS UKHRP WOQ WOW ~8M AAYXX CITATION 7QO 7XB 8FD 8FK AZQEC DWQXO FR3 K9. P64 PQEST PQUKI PRINS ABVAZ AFGXO AFNRJ 5PM |
| ID | FETCH-LOGICAL-b679t-b26885833e6e447aa5cf6fac5ee16fdbd0046248c7f19eaac9da2a1ea59bf6b93 |
| IEDL.DBID | RPM |
| ISSN | 1748-717X |
| IngestDate | Tue Oct 22 15:11:43 EDT 2024 Tue Sep 17 21:19:05 EDT 2024 Wed May 22 07:15:23 EDT 2024 Thu Oct 10 22:15:25 EDT 2024 Tue Nov 19 21:30:56 EST 2024 Tue Nov 12 23:35:15 EST 2024 Thu Sep 12 17:03:37 EDT 2024 Sat Nov 02 12:14:36 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b679t-b26885833e6e447aa5cf6fac5ee16fdbd0046248c7f19eaac9da2a1ea59bf6b93 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444363/ |
| PMID | 22824133 |
| PQID | 1080754629 |
| PQPubID | 55355 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0a37d8bcd21a413b8da566f41e88bb2a pubmedcentral_primary_oai_pubmedcentral_nih_gov_3444363 biomedcentral_primary_oai_biomedcentral_com_1748_717X_7_111 proquest_journals_1080754629 gale_infotracmisc_A534319421 gale_infotracacademiconefile_A534319421 crossref_primary_10_1186_1748_717X_7_111 pubmed_primary_22824133 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-07-23 |
| PublicationDateYYYYMMDD | 2012-07-23 |
| PublicationDate_xml | – month: 07 year: 2012 text: 2012-07-23 day: 23 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Radiation oncology (London, England) |
| PublicationTitleAlternate | Radiat Oncol |
| PublicationYear | 2012 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | EJ Hall (618_CR6) 2003; 56 B Dobler (618_CR32) 2010; 5 JD Ruben (618_CR37) 2008; 70 K Otto (618_CR13) 2008; 35 T Holmes (618_CR18) 2009; 74 S Cilla (618_CR3) 2011 B Brenner (618_CR36) 2003; 10 (ICRU) ICoRUaM (618_CR19) 2010 CL Tsai (618_CR11) 2010 CA McBain (618_CR29) 2009; 21 D Palma (618_CR14) 2008; 72 N Burridge (618_CR28) 2006; 66 L Cozzi (618_CR8) 2008; 89 GJ Budgell (618_CR33) 2001; 59 P Deb (618_CR26) 2009; 32 M Guckenberger (618_CR7) 2009; 93 P Ost (618_CR35) 2011; 79 JA Efstathiou (618_CR1) 2009; 27 S Manager (618_CR30) 2007; 85 J Alvarez-Moret (618_CR9) 2010; 5 C McBain (618_CR5) 2009; 75 I Paddick (618_CR21) 2000; 93 Suppl 3 F Foroudi (618_CR16) 2010; 81 BD Kavanagh (618_CR24) 2010; 76 LP Muren (618_CR34) 2006; 80 EJ Hall (618_CR38) 2006; 65 CH Hsieh (618_CR2) 2011; 6 BR Hindson (618_CR17) 2012; 56 CC Pan (618_CR25) 2003; 57 A Bertelsen (618_CR31) 2010; 95 TF Lee (618_CR4) 2011; 24 A Henry (618_CR27) 2006; 64 D Wolff (618_CR12) 2009; 93 MT Davidson (618_CR10) 2011; 80 N Hardcastle (618_CR15) 2010; 36 HA Gay (618_CR22) 2007; 23 P Wright (618_CR20) 2010; 49 JM Michalski (618_CR23) 2010; 76 |
| References_xml | – volume: 85 start-page: 207 year: 2007 ident: 618_CR30 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2007.04.037 contributor: fullname: S Manager – volume: 80 start-page: 98 year: 2006 ident: 618_CR34 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2006.06.015 contributor: fullname: LP Muren – volume-title: ICRU Report 83, Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) year: 2010 ident: 618_CR19 contributor: fullname: (ICRU) ICoRUaM – volume-title: Med Dosim year: 2010 ident: 618_CR11 contributor: fullname: CL Tsai – volume: 64 start-page: 1174 year: 2006 ident: 618_CR27 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2005.09.044 contributor: fullname: A Henry – volume: 75 start-page: 664 year: 2009 ident: 618_CR5 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2008.11.040 contributor: fullname: C McBain – volume: 80 start-page: 1550 year: 2011 ident: 618_CR10 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.10.024 contributor: fullname: MT Davidson – volume: 5 start-page: 95 year: 2010 ident: 618_CR32 publication-title: Radiat Oncol doi: 10.1186/1748-717X-5-95 contributor: fullname: B Dobler – volume: 93 start-page: 259 year: 2009 ident: 618_CR7 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2009.08.015 contributor: fullname: M Guckenberger – volume: 93 Suppl 3 start-page: 219 year: 2000 ident: 618_CR21 publication-title: J Neurosurg doi: 10.3171/jns.2000.93.supplement_3.0219 contributor: fullname: I Paddick – volume: 32 start-page: 51 year: 2009 ident: 618_CR26 publication-title: Australas Phys Eng Sci Med doi: 10.1007/BF03178629 contributor: fullname: P Deb – volume-title: et al year: 2011 ident: 618_CR3 contributor: fullname: S Cilla – volume: 35 start-page: 310 year: 2008 ident: 618_CR13 publication-title: Med Phys doi: 10.1118/1.2818738 contributor: fullname: K Otto – volume: 57 start-page: S217 year: 2003 ident: 618_CR25 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(03)01031-9 contributor: fullname: CC Pan – volume: 24 start-page: 196 year: 2011 ident: 618_CR4 publication-title: Clin Oncol (R Coll Radiol) doi: 10.1016/j.clon.2011.06.006 contributor: fullname: TF Lee – volume: 36 start-page: 264 year: 2010 ident: 618_CR15 publication-title: Med Dosim contributor: fullname: N Hardcastle – volume: 70 start-page: 1530 year: 2008 ident: 618_CR37 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2007.08.046 contributor: fullname: JD Ruben – volume: 76 start-page: S101 year: 2010 ident: 618_CR24 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.05.071 contributor: fullname: BD Kavanagh – volume: 27 start-page: 4055 year: 2009 ident: 618_CR1 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.5776 contributor: fullname: JA Efstathiou – volume: 93 start-page: 226 year: 2009 ident: 618_CR12 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2009.08.011 contributor: fullname: D Wolff – volume: 79 start-page: 920 year: 2011 ident: 618_CR35 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.04.025 contributor: fullname: P Ost – volume: 21 start-page: 385 year: 2009 ident: 618_CR29 publication-title: Clin Oncol (R Coll Radiol) doi: 10.1016/j.clon.2009.01.016 contributor: fullname: CA McBain – volume: 76 start-page: S123 year: 2010 ident: 618_CR23 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.03.078 contributor: fullname: JM Michalski – volume: 56 start-page: 18 year: 2012 ident: 618_CR17 publication-title: J Med Imaging Radiat Oncol doi: 10.1111/j.1754-9485.2011.02336.x contributor: fullname: BR Hindson – volume: 6 start-page: 75 year: 2011 ident: 618_CR2 publication-title: Radiat Oncol doi: 10.1186/1748-717X-6-75 contributor: fullname: CH Hsieh – volume: 95 start-page: 142 year: 2010 ident: 618_CR31 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2010.01.011 contributor: fullname: A Bertelsen – volume: 74 start-page: 1311 year: 2009 ident: 618_CR18 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.04.037 contributor: fullname: T Holmes – volume: 59 start-page: 31 year: 2001 ident: 618_CR33 publication-title: Radiother Oncol doi: 10.1016/S0167-8140(00)00281-4 contributor: fullname: GJ Budgell – volume: 72 start-page: 996 year: 2008 ident: 618_CR14 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2008.02.047 contributor: fullname: D Palma – volume: 10 start-page: 2051 year: 2003 ident: 618_CR36 publication-title: Oncol Rep contributor: fullname: B Brenner – volume: 23 start-page: 115 year: 2007 ident: 618_CR22 publication-title: Phys Med doi: 10.1016/j.ejmp.2007.07.001 contributor: fullname: HA Gay – volume: 66 start-page: 892 year: 2006 ident: 618_CR28 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2006.07.013 contributor: fullname: N Burridge – volume: 49 start-page: 1045 year: 2010 ident: 618_CR20 publication-title: Acta Oncol doi: 10.3109/0284186X.2010.498431 contributor: fullname: P Wright – volume: 5 start-page: 110 year: 2010 ident: 618_CR9 publication-title: Radiat Oncol doi: 10.1186/1748-717X-5-110 contributor: fullname: J Alvarez-Moret – volume: 81 start-page: 765 year: 2010 ident: 618_CR16 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.06.061 contributor: fullname: F Foroudi – volume: 89 start-page: 180 year: 2008 ident: 618_CR8 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2008.06.013 contributor: fullname: L Cozzi – volume: 65 start-page: 1 year: 2006 ident: 618_CR38 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2006.01.027 contributor: fullname: EJ Hall – volume: 56 start-page: 83 year: 2003 ident: 618_CR6 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(03)00073-7 contributor: fullname: EJ Hall |
| SSID | ssj0045309 |
| Score | 2.1605816 |
| Snippet | To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT) for bladder... Background To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT)... Doc number: 111 Abstract Background: To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with... BACKGROUND: To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy (VMAT)... Abstract Background To compare 3 Dimensional Conformal radiotherapy (3D-CRT) with Intensity Modulated Radiotherapy (IMRT) with Volumetric-Modulated Arc Therapy... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 111 |
| SubjectTerms | Bladder Bladder cancer Cancer Cancer therapies Care and treatment Comparative analysis Health aspects Health physics Humans Imaging, Three-Dimensional Intensity modulated radiation therapy Medical equipment and supplies industry Medical test kit industry Muscle, Skeletal - pathology Neoplasm Invasiveness Radiation Radiation dosimetry Radiation therapy Radiotherapy Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted - methods Radiotherapy, Conformal - methods Radiotherapy, Intensity-Modulated - methods Retrospective Studies Therapists Therapy Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - radiotherapy Volumetric modulated arc therapy |
| SummonAdditionalLinks | – databaseName: BiomedCentral dbid: RBZ link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07bxQxELYgSIgmvOEgIBdIQLHivPbaXlFdSKI0UPCQIhrLT3HSPdDtXaT8gPxvZrx7p5ikQTRb-LX2zHg8I898JuQN4n8kznylQkAHJcTK2tZXgYtkx4HX2mO-8-k39eVMHx0jTM77m2_wmZYfwGTWFTgdZ5WqGGbx3gGPQaAwfz38uVW6ouE5mmPXeEDxuWGAvzLbZ8WBlHH7r2vnK8dTGTp55Sw6uf8Pq3hA9geDk056CXlIbsXFI3L383Cl_phcTmhYdtM5vqzlqd89S0iXifIjKOjzlWb0vKPTPt59fUHny4DvfsWAxb2Gy_1h29AVwh0gv2mf3HVBYQQ633Twfxji3GLEPHUz1Hkr6lHsVk_Ij5Pj759Oq-FthspJ1a4rV0utMWMryiiEsrbxSSbrmxiZTMGFnPUqtFeJtdFa3wZbWxZt07okXcufkr3FchGfE6psM061TSw54Cx8mxiCahgXUkc95iPysWCY-d3jcBhExi5rgEgGKW2Q0kahezMi77bs3XXMjo-W15seIvuL8XMBMNIMG9mMLVdBOx9qZsEAcDpYsIiTYFFr52o7Im9ReAzqB5iTt0OaA6wVkbbMpOFgs7Wiht8dFC1hX_uyeit-ZtArXYZzVQ1Qth2RZ70k7qZbg_cMMwJ6qUJGi_WUNYvpr4wozoUQXPIX_0Xpl-QeWJM5lrnmB2RvvdrEV-R2Fzav8179A89qPaU priority: 500 providerName: BioMedCentral – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QF8WZpQT4gwSVqHDu2I04LbdULXACpt8hPsdI-0Ga3Un8A_7szdjaq1QMXLjnYjmPPjMczysw3hHxA_I_ImauU9-ig-FAZ07nKcxFN7XmjHeY7X_5Q36_02TnC5EylvjAmLMMDZ8Kd1oYrr63zDTOgcK32BiyQKFjQ2tomm0a1PDhTWQeLlqfgDjC3dQUOy9UI6sO0PJ3aKlUxLBxUJLovi_spwfjfV9Z3bqsykvLO1XTxlDwZbUo6z3t5Rh6E9XPy6Nv41_wF-TunfjMsVlg8y1E3VR6km0j5GTTklKQlvR7oIoe0727oauOxtFfw2JyVWHofTgbdIqIBspTm_K0bCjPQ1X6A78MU1waD4qldolrbUoeStX1Jfl2c__x6WY3lFyorVberbCO1xqSsIIMQypjWRRmNa0NgMnrrU2Kr0E5F1gVjXOdNY1gwbWejtB1_RY7Wm3V4Q6gybR0bE1m04O7Bsw3eq5ZxIXXQNZ-RzwUT-j8ZaqNH8OuyB4jUIwt7ZGGv0IOZkU8Hlk0vJt9Gy_tDvyBLi_lTA4hcP4pc_y-Rm5GPKBA9qgBYkzNjJgPsFcG0-nnLwSzrRAOfOylGwtF1ZfdBpPpRdQwJsVW1QNluRl5n6ZqW24CDDCsCeqlC7or9lD3rxe8EGs6FEFzyt_-DAMfkMdiNKWq54SfkaLfdh3fk4eD379MxvAWoTjqf priority: 102 providerName: Directory of Open Access Journals |
| Title | A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22824133 https://www.proquest.com/docview/1080754629 http://dx.doi.org/10.1186/1748-717X-7-111 https://pubmed.ncbi.nlm.nih.gov/PMC3444363 https://doaj.org/article/0a37d8bcd21a413b8da566f41e88bb2a |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYHhAXxJtAqXxAgku6m9iJHXHavtRLEeIhVVwiP2GlTVIlu5X6A_q_O-Mkq4beuOTgdzwPzyQznwn5iPgfniUmFtaig2JdrFRhYsu4VwvLUmkw3_n8h_h6KU9OESYnG3NhQtC-0avDel0d1qu_IbbyqjLzMU5s_u3imHHOWc7mMzID23B00Xv1yzO2KAYMn0Tmc7C4ZQw-y2UsYpBrBP8FLwNUN_snxX09OZkCgP9DNX3vnJrGUN47lM6ekaeDNUmX_aqfk0eufkEeXwz_y1-S2yW1Tbeq8NosQ83uzkHaeMpOoKBPRlrT646u-mD2zQ2tGouXejmLxb36Cv1BJmiLWAZITNpnbt1QGIFW2w7mhyGuFYbDU71GhdZSgzzVviK_zk5_Hp_Hw8ULsc5FsYl1mkuJ6Vgud5wLpTLjc69M5lySe6ttSGnl0gifFE4pU1iVqsSprNA-1wV7TfbqpnZvCRUqW_hU-cRrcPTgmTlrRZYwnksnFywiXyZEKK96kI0SYa-nNbBJJVKzRGqWAn2XiHweSbbrGLwamT9seoQknYwfCpr2TzkwV7lQTFipjU0TBSyipVVg7nqeOCm1TlVEPiFDlCj8sCajhhwGeFeE0SqXGQODrOApTLc_aQlCa6bVI0uVg9LoAlaryGBni4i86blrt9yRaSMiJnw3eZ9pDUhPgAsfpOXdf_d8T56AmRiClFO2T_Y27dZ9ILPObg_CJwx4fj_6fRDE8A4bYjpN |
| link.rule.ids | 108,230,315,729,782,786,866,887,2106,24946,27933,27934,53800,53802,75821,75822 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokYAL78JCAR-Q4JJuEjuxI05LH1pEt0KiSL1ZfsJKu9lqH5X6A_jfzDjJqqG3XnKwYzu2vxnPKDOfCfmI_B-BZTYRzqGD4nyidWUTx3jQqWO5tJjvPP4pzi7k0THS5BRdLkwM2rdmelDP5gf19E-Mrbyc22EXJzb8MTlknHNWsuEOuQ_ymqadk94oYF6wtGpZfDJZDsHmlgl4LReJSECykf4X_AxQ3uy_JPdZ72yKFP63FfWNk6ofRXnjWDp5cscJPSWPWzuUjprqZ-Ser5-TB5P2T_sL8ndE3WI1neOFW5ba7W2FdBEoO4KCJo1pRq9WdNqEwa-v6Xzh8Dow77C4UXyxPUgTXSILAsKANjlf1xR6oPPNCsaHLq40BtJTM0NVuKQW0bh8SX6dHJ8fjpP2yobElKJaJyYvpcRELl96zoXWhQ1l0LbwPiuDMy4mw3JpRcgqr7WtnM515nVRmVCaiu2R3XpR-9eECl2kIdchCwZcRHgW3jlRZIyX0suUDciX3uapy4aeQyFhdr8GFkkhChSiQAn0egbkc7fV24bRH5Ll7Ve_IhR6_ceCxfK3andRpZoJJ411eaYBWkY6DYZy4JmX0phcD8gnBJJCtQHfZHWb_QBzRQIuNSoYmHIVz2G4_d6bIO62X91BUbXqZhVZXkUBK1sNyKsGldvP7cA-IKKH1958-jUA00g03sLyzZ1bfiAPx-eTU3X67ez7W_IIjM0Y6pyzfbK7Xm78O7Kzcpv3UXz_AeapTcw |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF7RIlVceD8MBfaABBc3tnftXYtTaBoVQatKgNTbap8QKXGiPCr1B_C_mVk7UU1vcMlhX_Z6v5mdUWa-IeQd8n8ElttUOIcOivOp1rVNHeNBZ44V0mK-8-k3cX4pRydIk7Mr9RWD9q2ZHDXT2VEz-RVjKxczO9jGiQ0uzo4Z55xVbLBwYbBH7oLMZsXWUW-VMC9ZVndMPrmsBmB3yxQ8l8tUpCDdSAEMvgYocPZXovu0dz9FGv_byvrGbdWPpLxxNY0f_MemHpL7nT1Kh-2QR-SObx6Tg7PuH_cn5PeQuvlqMsPCW5baXdVCOg-UjaChTWea0qsVnbTh8OtrOps7LAvmHTa3CjDOB6miS2RDQDjQNvfrmsIKdLZZwfNhiSuNAfXUTFElLqlFVC6fkh_jk-_Hp2lXuiE1lajXqSkqKTGhy1eec6F1aUMVtC29z6vgjItJsVxaEfLaa21rpwude13WJlSmZs_IfjNv_AtChS6zUOiQBwOuIvyW3jlR5oxX0suMJeRj7wDVoqXpUEic3e-Bj6QQCQqRoAR6Pwn5sD3u3cToF8nq9tBPCIfe-rFhvvypupNUmWbCSWNdkWuAl5FOg8EceO6lNKbQCXmPYFKoPuCdrO6yIGCvSMSlhiUDk67mBTzusDcSxN72u7dwVJ3aWUW2V1HCl60T8rxF5u51t4BPiOhhtreffg9ANRKOd9B8-c8z35KDi9FYff18_uUVuQc2Z4x4Ltgh2V8vN_412Vu5zZsowX8AJYJQTA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+dosimetric+comparison+of+3D+conformal+vs+intensity+modulated+vs+volumetric+arc+radiation+therapy+for+muscle+invasive+bladder+cancer&rft.jtitle=Radiation+oncology+%28London%2C+England%29&rft.au=oudi%2C+Farshad&rft.au=Wilson%2C+Lesley&rft.au=Bressel%2C+Mathias&rft.au=Haworth%2C+Annette&rft.date=2012-07-23&rft.pub=BioMed+Central&rft.eissn=1748-717X&rft.volume=7&rft_id=info:doi/10.1186%2F1748-717X-7-111&rft.externalDocID=2772077231 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-717X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-717X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-717X&client=summon |